The Gene Panel is a new assay utilizing next generation sequencing (NGS) technology that allows for comprehensive genomic analysis of solid tumor samples. Because of the rigorously designed capture or amplicon sequencing strategy, Gene Panel makes NGS and data analysis more economical, flexible and efficient.
CD Genomics utilizes targeted genome sequencing to provide more efficient and accurate targeting of specific genes or mutations, and even detect low frequency variants in cancer-associated genes. Targeted genome sequencing facilitates the sequencing of a large number of genes and samples in a single, cost-effective assay.
We use capture-based next generation sequencing (Illumina platform) to target and analyze over 500 known tumor genes designed to detect variants and assess tumor mutational burden (TMB) and microsatellite instability (MSI) in tumor samples, allowing for the discovery of multiple positive tumor markers and novel drug targets at once. Our solid tumor panel sequencing service can be used to detect formalin-fixed, paraffin-embedded (FFPE) tissues such as lung cancer, melanoma cancer, ovarian cancer, and gastric cancer, etc. We also provide custom bioinformatics analysis services for you to perform targeted tumor gene analysis and comparative tumor tissue analysis in a short time, etc.
(Check the Gene List of Solid Tumor Panel (500 genes) for more genes.)
Collection: DNA samples (stored in TE buffer or equivalent), FFPE samples (recommended cryopreservation). Please make sure that the DNA is not degraded.
CD Genomics concentrates on disease genomics and our rapid NGS workflow, which maximize efficient and cost effective solid tumor panel sequencing services and bioinformatics support for our clients.